{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:14:55Z","timestamp":1783120495459,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To investigate aldo\u2013keto reductase 1C3 (AKR1C3) expression in T and B acute lymphoblastic leukemia\/lymphoma (ALL) patients. Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry (IHC) staining performance: Polyclonal Thermofisher scientific (Clone#PA523667), rabbit monoclonal Abcam [EPR16726] (ab209899) and Sigma\/Millipore anti-AKR1C3 antibody, mouse monoclonal, clone NP6.G6.A6, purified from hybridoma cell culture. Initial optimization was performed on cell line controls: HCT116 (negative control); genetically modified cell line HCT116 with AKR1C3 overexpression; Nalm and TF1 cell lines. Twenty normal bone marrows from archival B and T-ALL patient samples were subsequently examined. AKR1C3 expression levels in these samples were evaluated by immunohistochemistry, Protein Wes and quantitative RT-PCR. Sigma\/Millipore Anti-AKR1C3 antibody (mouse monoclonal, clone NP6.G6.A6) showed higher specificity compared to rabbit polyclonal antibody by immunohistochemistry. H-score was used to quantify percent of nuclear immunoreactivity for AKR1C3 with varying disease involvement. T-ALL samples had a higher H-score (172\u2013190) compared to B-ALL cases (H-score, 30\u2013160). The AKR1C3 expression in peripheral blood by Protein Wes and RT-qPCR showed concordance in relapsed\/refractory and\/or minimal residual T-ALL cases. Sigma\/Millipore Anti-AKR1C3 antibody and mouse monoclonal, clone NP6.G6.A6 can be used to aid in AKR1C expression of T-ALL and in cases of relapsed\/refractory and\/or minimal residual disease.<\/jats:p>","DOI":"10.1038\/s41598-022-09697-6","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T13:04:43Z","timestamp":1649250283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["AKR1C3 expression in T acute lymphoblastic leukemia\/lymphoma for clinical use as a biomarker"],"prefix":"10.1038","volume":"12","author":[{"given":"Deepti","family":"Reddi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon W.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Woolston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Aicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke D.","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei J.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill C.","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papadantonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia C. S.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"9697_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"9697_CR2","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger, T. & Abdul-Hay, M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer J. 7, e577 (2017).","journal-title":"Blood Cancer J."},{"key":"9697_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz, E. A. & Teachey, D. T. T-cell acute lymphoblastic leukemia. Hematol. Am. Soc. Hematol. Educ. Program. 2016, 580\u2013588 (2016).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"9697_CR4","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1080\/10428194.2019.1605071","volume":"60","author":"H Rafei","year":"2019","unstructured":"Rafei, H., Kantarjian, H. M. & Jabbour, E. J. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 60, 2606\u20132621 (2019).","journal-title":"Leuk Lymphoma."},{"key":"9697_CR5","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","volume":"21","author":"JM Goldberg","year":"2003","unstructured":"Goldberg, J. M. et al. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J. Clin. Oncol. 21, 3616\u20133622 (2003).","journal-title":"J. Clin. Oncol."},{"key":"9697_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","volume":"489","author":"TM Penning","year":"2019","unstructured":"Penning, T. M. AKR1C3 (type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase): Roles in malignancy and endocrine disorders. Mol. Cell. Endocrinol. 489, 82\u201391 (2019).","journal-title":"Mol. Cell. Endocrinol."},{"key":"9697_CR7","doi-asserted-by":"publisher","first-page":"e8147","DOI":"10.1371\/journal.pone.0008147","volume":"4","author":"FL Khanim","year":"2009","unstructured":"Khanim, F. L. et al. Combined bezafibrate and medroxyprogesterone acetate: Potential novel therapy for acute myeloid leukaemia. PLoS ONE 4, e8147 (2009).","journal-title":"PLoS ONE"},{"key":"9697_CR8","first-page":"505","volume":"63","author":"JC Desmond","year":"2003","unstructured":"Desmond, J. C. et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res. 63, 505\u2013512 (2003).","journal-title":"Cancer Res."},{"key":"9697_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1358\/dnp.2004.17.9.872570","volume":"17","author":"DR Bauman","year":"2004","unstructured":"Bauman, D. R., Steckelbroeck, S. & Penning, T. M. The roles of aldo-keto reductases in steroid hormone action. Drug News Perspect. 17, 563\u2013578 (2004).","journal-title":"Drug News Perspect."},{"key":"9697_CR10","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1182\/blood-2014-12-618900","volume":"126","author":"D Moradi Manesh","year":"2015","unstructured":"Moradi Manesh, D. et al. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood 126, 1193\u20131202 (2015).","journal-title":"Blood"},{"key":"9697_CR11","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-19-0551","volume":"25","author":"K Evans","year":"2019","unstructured":"Evans, K. et al. OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL. Clin. Cancer Res. 25, 4493\u20134503 (2019).","journal-title":"Clin. Cancer Res."},{"key":"9697_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00280-011-1671-3","volume":"68","author":"GK Abou-Alfa","year":"2011","unstructured":"Abou-Alfa, G. K. et al. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 68, 539\u2013545 (2011).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"9697_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/carcin\/bgn071","volume":"29","author":"CY Liu","year":"2008","unstructured":"Liu, C. Y. et al. Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia. Carcinogenesis 29, 984\u2013990 (2008).","journal-title":"Carcinogenesis"},{"key":"9697_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mrfmmm.2008.12.010","volume":"662","author":"J Birtwistle","year":"2009","unstructured":"Birtwistle, J. et al. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis. Mutat. Res. 662, 67\u201374 (2009).","journal-title":"Mutat. Res."},{"key":"9697_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bcp.2013.12.019","volume":"88","author":"SM Jamieson","year":"2014","unstructured":"Jamieson, S. M. et al. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem. Pharmacol. 88, 36\u201345 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"9697_CR16","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","volume":"70","author":"CP Guise","year":"2010","unstructured":"Guise, C. P. et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 70, 1573\u20131584 (2010).","journal-title":"Cancer Res."},{"key":"9697_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.bcp.2014.08.003","volume":"91","author":"J Wang","year":"2014","unstructured":"Wang, J. et al. Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. Biochem. Pharmacol. 91, 436\u2013446 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"9697_CR18","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1021\/acs.jmedchem.9b00090","volume":"62","author":"K Verma","year":"2019","unstructured":"Verma, K. et al. Potent and highly selective aldo-keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in acute myeloid leukemia and T-cell acute lymphoblastic leukemia. J. Med. Chem. 62, 3590\u20133616 (2019).","journal-title":"J. Med. Chem."},{"key":"9697_CR19","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41416-018-0014-0","volume":"118","author":"R Bortolozzi","year":"2018","unstructured":"Bortolozzi, R. et al. AKR1C enzymes sustain therapy resistance in paediatric T-ALL. Br. J. Cancer. 118, 985\u2013994 (2018).","journal-title":"Br. J. Cancer."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09697-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:11:30Z","timestamp":1669320690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09697-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9697"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09697-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1009027\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5809"}}